Literature DB >> 18365995

Pneumocystis pneumonia.

Laurie C D'Avignon1, Christina M Schofield, Duane R Hospenthal.   

Abstract

Pneumocystis is an opportunistic fungus that is a major cause of morbidity and mortality in immunocompromised hosts. Despite a decline in incidence with the advent of highly active antiretroviral therapy (HAART), Pneumocystis remains the most common opportunistic infection in patients with the acquired immunodeficiency syndrome (AIDS) and is an increasing cause of disease in patients with other forms of immunosuppression. Although there have been advances in the prevention and treatment of this infection, the mortality for Pneumocystis pneumonia (PCP) in the setting of AIDS remains 10 to 20%. The mortality for patients with other forms of immunosuppression is poorly defined but may actually be higher than that reported in the setting of AIDS. The continued severity of PCP in the AIDS population, its increasing frequency in other immunosuppressed populations, and increasing evidence that normal hosts may serve as a reservoir for the organism merit continued evaluation of the epidemiology, clinical presentation, diagnosis, and treatment of this infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18365995     DOI: 10.1055/s-2008-1063852

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  7 in total

1.  B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent.

Authors:  Teri R Hoyt; Erin Dobrinen; Irina Kochetkova; Nicole Meissner
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

2.  A new method for the detection of Pneumocystis jirovecii using flow cytometry.

Authors:  J Barbosa; C Bragada; S Costa-de-Oliveira; E Ricardo; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-16       Impact factor: 3.267

3.  Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?

Authors:  Melanie T Cushion
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

4.  Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia.

Authors:  Samir P Bhagwat; Terry W Wright; Francis Gigliotti
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 5.  Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia.

Authors:  Alessandro Allegra; Alessandro Tonacci; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

6.  Massive Cavitation by Pneumocystis jirovecii in an Immunocompromised Patient.

Authors:  Aldair Chaar-Hernandez; Jorge Montes; Maria C Rojas; Diego A Padilla-Mantilla; Abdelilah Lahmar; Juan F Toledo-Martinez; Francisco J Somoza-Cano
Journal:  Cureus       Date:  2022-05-26

Review 7.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.